The World Health Organization (WHO) Safety Report database shows that the number of ICI-related type 1 diabetes patients is increasing (11), which may be related to the increased use of anti-PD-1 and anti-PD-L1 therapies in various cancers. This evidence concerns the gene CD274 and type 1 diabetes mellitus.